ライフサイエンスコーパス: colon carcinoma

1 also confirmed in mouse prostate cancer and colon carcinoma.

2 n IFN-alpha-driven tumor microenvironment in colon carcinoma.

3 xymethane and dextran sodium sulfate-induced colon carcinoma.

4 s as a suppressor of spontaneous sarcoma and colon carcinoma.

5 the colitic microenvironment and associated colon carcinoma.

6 o as a therapeutic target in models of human colon carcinoma.

7 NR) may have independent prognostic value in colon carcinoma.

8 pressed in human multiple myeloma as well as colon carcinoma.

9 mber of tumor entities such as pancreatic or colon carcinoma.

10 ls contributes to the hematogenous spread of colon carcinoma.

11 pithelial to mesenchymal transition (EMT) of colon carcinoma.

12 rall survival (OS) after primary surgery for colon carcinoma.

13 tem cell self-renewal and is dysregulated in colon carcinoma.

14 get to prevent the metastatic progression of colon carcinoma.

15 repeat genotyping to study the evolution of colon carcinoma.

16 mutations can be found in other cancers than colon carcinoma.

17 igen over 7 d using a syngeneic rat model of colon carcinoma.

18 18)F-FLT uptake in arthritic ankles and CT26 colon carcinomas.

19 ay lead to improved therapeutic regimens for colon carcinomas.

20 of tumor growth in mice with implanted CT-26 colon carcinomas.

21 of microsatellite instability (MSI) in human colon carcinomas.

22 ar matrix surrounding tumor cells, including colon carcinomas.

23 brin, but not fibrinogen, receptor on LS174T colon carcinomas.

24 nous dissemination of tumor cells, including colon carcinomas.

25 dendrimer was evaluated in mice bearing C-26 colon carcinomas.

26 f antiangiogenesis in ectopic and orthotopic colon carcinomas.

27 ely correlated with PTEN expression in human colon carcinomas.

28 spontaneously developed small intestine and colon carcinomas.

29 n several epithelial cancers, including many colon carcinomas.

30 drome, 28 for acute myeloid leukemia, 36 for colon carcinoma, 33 for osteogenic sarcoma, and 12 for f

31 MCF-7 (human breast carcinoma), HT-29 (human colon carcinoma), A2780 (human ovarian carcinoma), and A

32 We previously reported that colon carcinomas, adenomas, and hyperplastic polyps exhi

33 nude mice bearing subcutaneous LS 174T human colon carcinoma and C6 rat glioma tumors.

34 ct on mRNA levels in primary enterocytes and colon carcinoma and hepatoma cells.

35 D8(+) T effector cells in tumor models (CT26 colon carcinoma and ID8-VEGF ovarian carcinoma).

36 Another variant was identified in a colon carcinoma and is altered at position 289 from lysi

37 been linked to many human cancers including colon carcinoma and melanoma.

38 sed expression of claudin-1 in human primary colon carcinoma and metastasis and in cell lines derived

39 cumulated on the lateral interfaces of human colon carcinoma and normal intestinal epithelial cells b

40 ion between MET and TNS4 expression in human colon carcinoma and ovarian carcinoma suggests TNS4 play

41 nism for how RhoC expression is regulated in colon carcinoma and substantiate its utility as a progno

42 models of human cancer, including LoVo human colon carcinoma and U87-MG human glioblastoma, when dose

43 diators associated with inflammation-induced colon carcinomas and colon tumor survival.

44 show that USP39 is up-regulated in lung and colon carcinomas and its expression correlates with KRAS

45 Quinacrine induced apoptosis in colon carcinomas and potentiated the cytotoxic activity

46 p85beta expression is elevated in breast and colon carcinomas and that its increased expression corre

47 f ST6Gal-I occurs in many cancers, including colon carcinoma, and correlates with metastasis and poor

48 ciated with multiple malignancies, including colon carcinoma, and with ectodermal and mesoendodermal

49 adenomas, human FAP adenomas, human sporadic colon carcinomas, and in the intestine of apc(mcr) mutan

50 oxygenase-2 (COX-2) is up-regulated in human colon carcinomas, and its inhibition is associated with

51 man lung carcinoma, Colo205 and LS174T human colon carcinomas, and U87MG human glioblastoma multiform

52 FET cells, derived from an early-stage colon carcinoma, are nontumorigenic in athymic mice.

53 are as effective in treating the murine C26 colon carcinoma as Doxil, a commercial liposome doxorubi

54 ranging from 0.05 to 2.45 muM against HT-29 colon carcinoma as well as MCF-7 and MDA-MB-231 mammary

55 antimetastatic activity in a murine model of colon carcinoma, as well as potent antiadhesive properti

56 Melanoma- or colon carcinoma-bearing C57BL/6 mice did not develop GvH

57 We injected arthritic, healthy, and CT26 colon carcinoma-bearing mice with (18)F-FLT before stati

58 is by 10 wk post-infection, progressing into colon carcinoma by 20 wk post-infection, with pronounced

59 ained significant inhibitory effects against colon carcinoma (CaCo-2) cells.

60 ity and CaSR protein expression in the human colon carcinoma CBS cells, which possessed a functional

61 Moreover, CEA and CD44v cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin at el

62 ne model, leads to a significant decrease in colon carcinoma cell adhesion, migration and metastasis.

63 ves have been synthesized and evaluated in a colon carcinoma cell growth inhibition assay using HCT11

64 ncer cell cytotoxicity assays with the human colon carcinoma cell line (HT-29) showed that internaliz

65 n largazole 1 in growth inhibition of HCT116 colon carcinoma cell line and in inducing increases in g

66 isense inhibition of SIM2-s in a RKO-derived colon carcinoma cell line causes growth inhibition, apop

67 We recently demonstrated that the LS174T colon carcinoma cell line expresses the CD44 glycoform k

68 We identified LSR splice variants in the colon carcinoma cell line HCT116 and disrupted the LSR g

69 ach to a study of gene expression in the RKO colon carcinoma cell line in response to varying dosage

70 tudies, and blot rolling assays of LS174T, a colon carcinoma cell line known to interact with E-selec

71 YAMC cells, the mouse colon carcinoma cell line MC38, the mouse macrophage cel

72 ominant MHC class I tumor antigen of a mouse colon carcinoma cell line stimulates a tumor-specific T-

73 x1-mediated ROS generation in the HT29 human colon carcinoma cell line through a Rac-dependent mechan

74 Treatment of a human colon carcinoma cell line with alpha-DABA versus gamma-D

75 modulates a subset of p53 target genes in a colon carcinoma cell line, consistent with the observati

76 inhibited cell growth of an aggressive human colon carcinoma cell line, FET6alphaS26X, which harbors

77 ation, apoptosis and cell cycle in the human colon carcinoma cell line, HT-29.

78 unilaterally by the CT26 wild type (CT26WT) colon carcinoma cell line.

79 iated cytotoxicity against Colo-205, a human colon carcinoma cell line.

80 valuated in vitro using the HCT116/LUC human colon carcinoma cell line.

81 pathways controlled by p53, isogeneic human colon carcinoma cell lines (HCT116) differing only in th

82 tumorigenicity, and metastasis in Smad4-null colon carcinoma cell lines (MC38 and SW620) and in those

83 imulation were immunoprecipitated from human colon carcinoma cell lines and identified by mass spectr

84 e in murine liver and human HCC, breast, and colon carcinoma cell lines and specimens.

85 Thus, six of seven colon carcinoma cell lines from the NCI Anticancer Drug

86 -resistant and metastatic phenotype in human colon carcinoma cell lines in vitro.

87 We report MRN deficiency in three of seven colon carcinoma cell lines of the NCI Anticancer Drug Sc

88 id cells resulting from the culture of human colon carcinoma cell lines or primary mouse epithelial c

89 glycosylation profiles of the isogenic human colon carcinoma cell lines SW480 (primary tumor) and SW6

90 T61, was used to block HH signaling in human colon carcinoma cell lines that express HH signaling com

91 OCUS, Mahlavu liver, MCF7 breast, and HCT116 colon carcinoma cell lines.

92 enhanced motility and invasiveness of other colon carcinoma cell lines.

93 abolished the clonogenicity of all six human colon carcinoma cell lines.

94 e dependent on JMJD1A in both renal cell and colon carcinoma cell lines.

95 ve NF-kappaB activation in five of six human colon carcinoma cell lines; this activation is inhibited

96 t (CRMP-2L) alone binds ROCK II and inhibits colon carcinoma cell migration and invasion.

97 ST6Gal-I knockdown and forced overexpression colon carcinoma cell models, we find that alpha2-6 sialy

98 so known as ArhGEF28 or p190RhoGEF) promotes colon carcinoma cell motility and tumor progression via

99 h, structure-dependent toxicity to the human colon carcinoma cell-line HCT116 p53(++), causing dramat

100 Syngenic TWIST1-positive colon carcinoma cells (CT26) that invaded tissues surrou

101 and on the second day they were given mouse colon carcinoma cells (CT26).

102 In human colon carcinoma cells (HCT-8) and lung carcinoma cells (

103 is of intracellular Ca(2+) handling in human colon carcinoma cells (HT29) versus normal human mucosa

104 al transition (EMT) of highly differentiated colon carcinoma cells (LIM1863 cells).

105 0 times less toxic than free DOX toward C-26 colon carcinoma cells after exposure for 72 h.

106 esis, we genetically engineered HCT116 human colon carcinoma cells and 4T1 mouse mammary carcinoma ce

107 These analogues inhibit LSD1 in human colon carcinoma cells and affect a reexpression of multi

108 the expression of CD44 and/or CEA in LS174T colon carcinoma cells and analyzed their ability to meta

109 s coated with CEA immunopurified from LS174T colon carcinoma cells and selectins as substrate reveal

110 ve, i.e. autophosphorylated, ErbB2 in HCT116 colon carcinoma cells and TA3/St mammary carcinoma cells

111 been shown to be active in human breast and colon carcinoma cells and to promote their invasion thro

112 tribute to aberrant COX-2 expression in HT29 colon carcinoma cells and to reveal the role of platelet

113 romoter of the p21 gene in unstressed HCT116 colon carcinoma cells are localized within a region of r

114 We found that Ca(2+) stores in colon carcinoma cells are partially depleted relative to

115 lity to these viruses and observed that HT29 colon carcinoma cells are susceptible to infection by ne

116 ose findings by showing that T84 and Colo205 colon carcinoma cells bind selectins via sialidase-sensi

117 Pdcd4 suppresses tumor progression in human colon carcinoma cells by the novel mechanism of down-reg

118 Basal CXCR4 promoter activity in HCT116 colon carcinoma cells deleted of p53 [HCT116(p53KO)] was

119 In DLD-1 colon carcinoma cells depleted of Galpha13, gastrin-indu

120 pin RNA (shRNA) knockdown of fascin in human colon carcinoma cells derived from an aggressive primary

121 treated with Taxol, slippage-resistant HT29 colon carcinoma cells display robust Cdk1 activity and e

122 die in mitosis, whereas slippage-prone DLD-1 colon carcinoma cells display weak Cdk1 activity and par

123 Heparin diminishes the avidity of colon carcinoma cells for P- and L-selectin, which may c

124 is a key survival factor that protects human colon carcinoma cells from TNF-related apoptosis-inducin

125 ance the cytotoxicity of these drugs against colon carcinoma cells in vitro demonstrating a clear syn

126 shown that ETS1 represses tumorigenicity of colon carcinoma cells in vivo, and that the p42-ETS1 pro

127 xpression is critical for tumor formation by colon carcinoma cells in vivo.

128 it proliferation, migration, and invasion of colon carcinoma cells indicating tumor suppressor activi

129 e show that PTEN deletion in HCT116 and DLD1 colon carcinoma cells leads to suppression of CHK1 and C

130 Selection of irinotecan resistance in colon carcinoma cells led to a greater proportion of CSC

131 t variant isoforms of CD44 (CD44v) on LS174T colon carcinoma cells possess P-/L-/E-selectin binding a

132 that CD44 variant isoforms (CD44v) on LS174T colon carcinoma cells possess selectin binding activity.

133 tion of MAP1D expression by shRNA in HCT-116 colon carcinoma cells reduces anchorage-independant grow

134 y analysis of Pdcd4-overexpressing RKO human colon carcinoma cells revealed MAP4K1 as the sole target

135 In contrast, colon carcinoma cells showed mixed currents composed of

136 ic and metastatic profile in both breast and colon carcinoma cells than plasma from mice treated with

137 tected high levels of RhoA activity in HCA-7 colon carcinoma cells that constitutively express COX-2.

138 r, JW55 inhibited canonical Wnt signaling in colon carcinoma cells that contained mutations in either

139 formed mouse embryonic fibroblasts and HT-29 colon carcinoma cells that express a dominant negative P

140 gs, down-regulation of Hsp27 in HCT116 human colon carcinoma cells that express this heat shock prote

141 and alpha2beta1 integrins on the surface of colon carcinoma cells through the disintegrin domain.

142 S1 protein bypasses a defect in apoptosis in colon carcinoma cells through the up-regulation of caspa

143 ut enabled quiescent HD6, SW480, and colo320 colon carcinoma cells to acquire some biochemical charac

144 itro and in vivo Exposing human lymphoma and colon carcinoma cells to AZD3965 increased MCT4-dependen

145 Serum starvation induced HD6 colon carcinoma cells to enter a quiescent G0 state, cha

146 ective sensitization of the metastatic human colon carcinoma cells to FasL-induced apoptosis.

147 nd potent activity in sensitization of human colon carcinoma cells to FasL-induced apoptosis.

148 fectively modulate Fas function to sensitize colon carcinoma cells to FasL-induced apoptosis.

149 Exposure of HCT116 human colon carcinoma cells to reactive oxygen species, genera

150 We found that exposure of HT-29 human colon carcinoma cells to TNF for up to 20 days reduced t

151 shown that COX-2 inhibition sensitizes human colon carcinoma cells to tumor necrosis factor-related a

152 hibition (GI50) value for batracylin in HT29 colon carcinoma cells was 10 micromol/L.

153 LoVo colon carcinoma cells were transfected with BCMO1 small

154 (shRNA)-mediated attenuation of ST6Gal-I in colon carcinoma cells with elevated endogenous expressio

155 Utilizing an isogenic panel of colon carcinoma cells with K-RAS or N-RAS variations, we

156 N null PC3 prostate and PIK3CA mutant HCT116 colon carcinoma cells with PI-103 resulted in a concentr

157 In HCT116 human colon carcinoma cells, 28c and 40f inhibited the Aurora-

158 strand breaks, activated DNA repair in human colon carcinoma cells, and effectively suppressed tumour

159 or cells, induce DNA damage and apoptosis in colon carcinoma cells, and reduce tumor size in animal m

160 ransport chain (ETC) in spermatogenic and in colon carcinoma cells, and silencing of either Fer or Fe

161 man wild-type p53- and p21-expressing HCT116 colon carcinoma cells, as well as in p53-null counterpar

162 used to deliver the doxorubicin to CT.26-WT colon carcinoma cells, eliciting a therapeutic response.

163 We show that in KM12C colon carcinoma cells, expression of kinase-deficient Sr

164 In colon carcinoma cells, Jerky facilitates Wnt signalling

165 In human colon carcinoma cells, Rgnef forms a complex with FAK an

166 When overexpressed in SW480 colon carcinoma cells, Sox17 represses beta-catenin/TCF

167 In human colon carcinoma cells, treatment with the Gli small-mole

168 In zebrafish epithelia and human colon carcinoma cells, Trpv6/TRPV6 elevated intracellula

169 ith cytoplasmic extracts of untreated HCT116 colon carcinoma cells, we identified the DEAD-box RNA he

170 etion was observed in both HT1080 and HCT116 colon carcinoma cells, where p21 was induced by DNA-dama

171 with CD44 immunopurified from LS174T or T84 colon carcinoma cells, which express primarily CD44v, ef

172 ice through intrasplenic inoculation of MC38 colon carcinoma cells.

173 and both MUC6 and MUC5AC expression in LS180 colon carcinoma cells.

174 anti-inflammatory effects in vitro using T84 colon carcinoma cells.

175 well as BaxBak double knockout HCT116 human colon carcinoma cells.

176 pregulate Fas expression in metastatic human colon carcinoma cells.

177 ctable by (1)H and (31)P MRS in prostate and colon carcinoma cells.

178 activity when combined with AZD7762 in human colon carcinoma cells.

179 arly S-phase, leading to cell death in human colon carcinoma cells.

180 e basis for its unique cytotoxic activity in colon carcinoma cells.

181 ses after intrasplenic/portal inoculation of colon carcinoma cells.

182 AP, Rap1GAP expression was silenced in human colon carcinoma cells.

183 pon DNA damage responses in human breast and colon carcinoma cells.

184 a in facilitating invasion and metastasis of colon carcinoma cells.

185 of macrophages to activate Wnt signaling in colon carcinoma cells.

186 cyclooxygenase-2/prostaglandin E(2) in HCA7 colon carcinoma cells.

187 al P-, but not E- or L-, selectin ligands on colon carcinoma cells.

188 activation of PPARdelta up-regulated VEGF in colon carcinoma cells.

189 ated kinases 1 and 2 (ERK1/2) in HT-29 human colon carcinoma cells.

190 reticulum retention sequence into GEO human colon carcinoma cells.

191 cytotoxic activity in human osteosarcoma and colon carcinoma cells.

192 ted legume species towards MMP-9 activity in colon carcinoma cells.

193 matrix adhesion molecules in human SW480-ADH colon carcinoma cells.

194 d CTL-mediated and FasL-induced apoptosis of colon carcinoma cells.

195 of colonic biopsy samples and polarized T84 colon carcinoma cells.

196 mouse on the growth of B16 melanoma or CT26 colon carcinoma cells.

197 linkage may mediate FAK activation in DLD-1 colon carcinoma cells.

198 arnessed to the reprogrammed mitochondria of colon carcinoma cells.

199 cell migration, as well as invasion of human colon carcinoma cells.

200 chanisms for hypoxic MYC inhibition in human colon carcinoma cells.

201 interesting activity against CA-4-resistant colon-carcinoma cells and multidrug-resistant leukemia c

202 observed that both apoptotic and necroptotic colon carcinoma CT26 cells efficiently immunized mice ag

203 g and presentation assays in HeLa and murine colon carcinoma (CT26) cells showed that these inhibitor

204 Parent colon carcinoma (CT26) cells transduced with a large amo

205 Here, we demonstrate that 5-FU-generated colon carcinoma debris stimulates the growth of a subthr

206 aecalis across monolayers of polarized human colon carcinoma-derived T84 cells.

207 ransfusion inhibited growth of both lung and colon carcinoma ectopic tumors, whereas blockade of miR-

208 ll lymphoma, neuroblastoma, and prostate and colon carcinomas, either as a single agent or in combina

209 The stromal cells within colon carcinoma express high levels of the platelet-deri

210 Although human colon carcinomas express TRAIL receptors, they can also

211 Resected, stage III colon carcinomas from patients (N = 2,686) randomly assi

212 ntial, revealing selectivity against HCT-15 (colon carcinoma) (GI50 approximately 74 mug/mL).

213 esquiterpenoid content; the IC(50) values on colon carcinoma, glioblastoma, and breast adenocarcinoma

214 intestinal epithelial cell line derived from colon carcinoma grown on semipermeable tissue culture in

215 survival in vitro, inhibits T-HEp3 and SW620 colon carcinoma growth in vivo.

216 Colon carcinoma HCT 116 cells were cultured and grown in

217 ved from extensive testing against the human colon carcinoma HCT-116 and the 60-cell-line panel at th

218 However, in the human colon carcinoma HCT-116 cell line, which is deficient in

219 amides A-C showed cytotoxicity against human colon carcinoma (HCT-116) cells with IC(50) values betwe

220 Here we show that human colon carcinoma (HCT-8) cells can exhibit a dissociative

221 Human colon carcinoma (HCT-8) cells show a stable transition f

222 n splicing at the genome-wide level in human colon carcinoma HCT116 and breast carcinoma MCF7 cells.

223 /MS for large-scale phosphoproteomics of the colon carcinoma HCT116 cell line.

224 induced demethylation of CDKN2A promoter in colon carcinoma HCT116 cells and its reactivation after

225 n, we tested TOP1mt KO fibroblasts and human colon carcinoma HCT116 cells and measured mtDNA after 3-

226 mosome instability induced in cultured human colon carcinoma HCT116 cells by the antitumor radiomimet

227 5-Fluorouracil treatment of colon carcinoma HCT116 cells expressing WT p53 results i

228 In human colon carcinoma HCT116 cells with wild-type (wt) p53, ga

229 tigate global DNA methylation changes, human colon carcinoma HCT116 cells, which were hypomorphic for

230 ntly elevated in DNMT1-/- or DNMT3B-/- human colon carcinoma (HCT116) cells.

231 After a short dose of camptothecin in human colon carcinoma HT29 cells, DNA replication was inhibite

232 ession is seen in some poorly differentiated colon carcinomas in humans.

233 Using Colo205 human colon carcinomas in nude mice as a model, we found that

234 egrin enhances the tumorigenic properties of colon carcinoma, including activation of autocrine TGF-b

235 stable overexpression in Ras-induced murine colon carcinomas increased microvascular densities and v

236 The recently cloned colon carcinoma kinase 4 (CCK4) oncogene contains an evo

237 is more stable than the interactions of the colon carcinoma kinase 4 transmembrane domain.

238 e kinase superfamily initially identified as colon carcinoma kinase-4, is highly expressed in various

239 n two human embryonic stem cell lines, human colon carcinoma line HCT116, and mouse embryonic stem ce

240 Moreover, in the various RAS mutant colon carcinoma lines, the transforming growth factor-al

241 For CT26 colon carcinoma liver metastases, inhibition of both VEG

242 T6Gal-I, a feature that is characteristic of colon carcinoma, may confer tumor cells with a selective

243 145 and LNCaP (prostate carcinoma), HCT-116 (colon carcinoma), MCF-7 (breast carcinoma) and NCI-H460

244 Three cell lines were employed: DLD1 (human colon carcinoma), MCF7 (human breast carcinoma) and NCI/

245 ications (PTMs), in the layers of the HCT116 colon carcinoma MCTS.

246 with ulcerative colitis and tumors including colon carcinoma, melanoma, hepatic carcinoma, ovarian ca

247 ble target for therapeutics aimed at curbing colon carcinoma metastasis.

248 itabine and vorinostat cooperate to suppress colon carcinoma metastasis.

249 t are required for cachexia in the mouse C26 colon carcinoma model of cancer.

250 Using a transplantable colon carcinoma model, we found that CD8(+) T cells beca

251 murine hepatocellular and colitis-associated colon carcinoma models, and this was associated with red

252 ty against both the L1210 leukemia and CT-26 colon carcinoma models.

253 udies identify Rgnef as a novel regulator of colon carcinoma motility and invasion, and they show tha

254 ) imaging mass spectrometry (IMS) in HCT 116 colon carcinoma multicellular spheroids to assess the di

255 okines in a clinical cohort of patients with colon carcinoma (n = 378).

256 location were determined in stage II and III colon carcinomas (n = 160) and normal mucosa (n = 25) by

257 ermined in patients with TNM stage II or III colon carcinomas (n = 2,693) who participated in randomi

258 In a mouse xenograft model of human colon carcinoma, nal-IRI dosing could achieve higher int

259 However, human colon carcinoma often deregulates the Fas signaling path

260 n HHD model in which HLA-A2(neg) tumor (MC38 colon carcinoma or B16 melanoma) cells are not recognize

261 When injected i.v. in mice bearing CT26 colon carcinoma or B16 melanoma, the 4PD nanoparticles p

262 The LIM 1863 colon carcinoma organoid undergoes epithelial-mesenchyma

263 In colon carcinoma patients, the contingent of circulating

264 they show that a Rgnef-FAK linkage promotes colon carcinoma progression in vivo.

265 comparatively investigated their effects on colon carcinoma proliferation, a) in vitro against colon

266 t CD44v is a functional P-selectin ligand on colon carcinoma provides a novel perspective on the enha

267 lso to other tumor types, including lung and colon carcinomas regardless of their BRAF status.

268 ability of human T lymphocytes to infiltrate colon carcinoma remain unclear.

269 mice bearing 4T1 mammary carcinoma and MC38 colon carcinoma, respectively.

270 Human colon carcinoma (RKO36), mouse sarcoma (SA-NH), along wi

271 types of cancers (e.g., breast carcinoma and colon carcinoma), S664-pTSC2 seemed to be a more sensiti

272 te that expression of CD103/beta(7) in human colon carcinoma-specific CTL is synergistically enhanced

273 es, exerts growth inhibitory effects against colon carcinoma, suggesting a nutraceutical potential in

274 (MEF2C), tumor suppressor pathway (p53) and colon carcinoma survival (beta-catenin).

275 er a human Kaposi's sarcoma (SLK) or a human colon carcinoma (SW1222).

276 50 muM against Cisplatin-Resistant SKOV3 and colon carcinoma SW480 cell lines.

277 In the CT26 mouse model of colon carcinoma, therapeutic vaccination with a lead Psi

278 n of smMLCK decreased (19.5 +/- 4.7 fold) in colon carcinoma tissues compared to normal colon tissues

279 We used a spheroid model of colon carcinoma to analyze integrin dynamics as a functi

280 sifies the human protein encoded by immature colon carcinoma transcript-1 (ICT1) as one of a family o

281 ry tumor with SAR in patients with stage III colon carcinomas treated with adjuvant chemotherapy.

282 hemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin.

283 therapeutic potential in an immunocompetent colon carcinoma tumor model.

284 ith the TSA mammary adenocarcinoma and MCA38 colon carcinoma tumor models that show little response t

285 When syngeneic murine CT26 colon carcinoma tumors (BALB/c) and B16 melanoma and Lew

286 and edema in the invasive areas of CT26.CL25 colon carcinoma tumors as shown by CD31 IHC.

287 d orally, mastic oil inhibited the growth of colon carcinoma tumors in mice.

288 One person died from colon carcinoma unrelated to study medication.

289 mic imbalances of chromosome 8 in 51 primary colon carcinomas using a custom-designed genomic array c

290 was measured in arthritic ankles and in CT26 colon carcinomas when the mice breathed oxygen and were

291 ls: mouse hepatocellular carcinoma and human colon carcinoma, whereby the metabolism has been profile

292 CaSR expression was weak in colon carcinomas with a more-differentiated histologic p

293 is essential for both SLK sarcoma and SW1222 colon carcinoma xenograft growth.

294 re, berberine suppresses the growth of human colon carcinoma xenograft in nude mice in an RXRalpha-de

295 nd robust in vivo efficacy in human lung and colon carcinoma xenograft models.

296 ses as well as growth of subcutaneous HCT116 colon carcinoma xenograft tumors, without affecting body

297 acy studies it inhibited the growth of SW620 colon carcinoma xenografts following oral administration

298 sly that the endothelium of vessels in human colon carcinoma xenografts in mice is a mosaic structure

299 of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice.

300 og on the tumor growth of NTR1-positive HT29 colon carcinoma xenografts.